EVAg

Human Immunodeficiency Virus (HIV) drug resistance remains a significant health issue that challenges treatment and prevention. The objective of this 3-week course is to learn bioinformatics techniques for the analysis of next-generation HIV sequencing results. This covers both HIV-1 and HIV-2. Teaching objectives include data curation, alignment, phylogenetics for typing, identification of drug resistance mutations, production of a resistance score, and interpretation. This course does not include genotyping itself, only sequence analysis and interpretation, as described above.

This clone belongs to a unique set of HIV-2 biological clones from West African immigrants in The Netherlands. Clones were obtained from patients with non-progressive, aviremic or progressive, viremic HIV-2 infection.

This clone belongs to a unique set of HIV-2 biological clones from West African immigrants in The Netherlands. Clones were obtained from patients with non-progressive, aviremic or progressive, viremic HIV-2 infection.

This clone belongs to a unique set of HIV-2 biological clones from West African immigrants in The Netherlands. Clones were obtained from patients with non-progressive, aviremic or progressive, viremic HIV-2 infection.

This clone belongs to a unique set of HIV-2 biological clones from West African immigrants in The Netherlands. Clones were obtained from patients with non-progressive, aviremic or progressive, viremic HIV-2 infection.

This clone belongs to a unique set of HIV-2 biological clones from West African immigrants in The Netherlands. Clones were obtained from patients with non-progressive, aviremic or progressive, viremic HIV-2 infection.

This clone belongs to a unique set of HIV-2 biological clones from West African immigrants in The Netherlands. Clones were obtained from patients with non-progressive, aviremic or progressive, viremic HIV-2 infection.

This clone belongs to a unique set of HIV-2 biological clones from West African immigrants in The Netherlands. Clones were obtained from patients with non-progressive, aviremic or progressive, viremic HIV-2 infection.

This clone belongs to a unique set of HIV-2 biological clones from West African immigrants in The Netherlands. Clones were obtained from patients with non-progressive, aviremic or progressive, viremic HIV-2 infection.

This clone belongs to a unique set of HIV-2 biological clones from West African immigrants in The Netherlands. Clones were obtained from patients with non-progressive, aviremic or progressive, viremic HIV-2 infection.

This clone belongs to a unique set of HIV-2 biological clones from West African immigrants in The Netherlands. Clones were obtained from patients with non-progressive, aviremic or progressive, viremic HIV-2 infection.

This clone belongs to a unique set of HIV-2 biological clones from West African immigrants in The Netherlands. Clones were obtained from patients with non-progressive, aviremic or progressive, viremic HIV-2 infection.

This clone belongs to a unique set of HIV-2 biological clones from West African immigrants in The Netherlands. Clones were obtained from patients with non-progressive, aviremic or progressive, viremic HIV-2 infection.

This clone belongs to a unique set of HIV-2 biological clones from West African immigrants in The Netherlands. Clones were obtained from patients with non-progressive, aviremic or progressive, viremic HIV-2 infection.